Every material Form 8-K NEONC TECHNOLOGIES HOLDINGS, INC. has filed with the SEC since October 22, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
NeOnc reported third-quarter 2026 results, with its net loss falling to $4.4 million from $8.6 million in the year-earlier quarter and total operating expenses declining to $5.8 million from $6.9 million. Cash and cash equivalents rose to $6.2 million at September 30, 2026, helped by a September registered direct offering of approximately $15 million gross, and the company said it will present NEO100 and NEO212 data on November 13, 2026.
Net loss attributable to common stockholders was $7.3 million, or $(0.28) per share, versus $8.6 million, or $(0.45) per share, in Q3 2025; the figure includes $2.8 million of noncash deemed dividends.
Cash and cash equivalents were approximately $6.2 million at September 30, 2026, up from approximately $2.0 million at June 30, 2026.
R&D expenses were $1.3 million, compared with $0.7 million in Q3 2025, while G&A expenses fell to $0.6 million from $0.9 million.
Data from NEO100 and NEO212 will be presented in two posters on November 13, 2026, at the Society for Neuro-Oncology Annual Meeting in Philadelphia.
NeOnc Technologies Holdings announced that data from its intranasal NEO100 and oral NEO212 programs will be presented in two posters on November 13, 2026, at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia. The filing is an announcement of scheduled presentations and contains no financial results, guidance, or new financing terms.
Two poster presentations scheduled for Friday, November 13, 2026, 7:30 to 9:30 p.m. EST, at the Pennsylvania Convention Center in Philadelphia
NEO100 poster: updated Phase 1/2a results in recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma, presented by Thomas C. Chen, MD, PhD
NEO212 poster: Phase 1 safety, pharmacokinetics and early activity signals in TMZ-Resistant recurrent GBM, presented by Josh Neman, PhD
Both NEO100 and NEO212 remain investigational and have not been approved by any regulatory authority
NeOnc furnished three press releases dated October 16, 21 and 22, 2026, covering an early reported improvement in one compassionate-use patient in Abu Dhabi, a non-binding memorandum of understanding with the Department of Health Abu Dhabi, and a scheduled television segment. The filing contains no financial results, and the company states that the single-patient observations do not establish safety or efficacy, so the near-term effect on shareholders is unclear.
October 16: a three-year-old boy treated with investigational intranasal NEO100 under the Compassionate Care program is reported to be breathing without ventilator support; the company says one patient does not establish that NEO100 caused
October 21: the MoU is not a binding contract, runs for two years, and can be ended with at least three months' notice; any regional presence would require a separate agreement
October 21: two children are currently receiving NEO100 in Abu Dhabi, with a third expected to be onboarded from India this week
October 22: segment airs Sunday, October 25, 2026, at 5:30 p.m. ET on Fox Business Network; air dates are subject to change
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NEONC TECHNOLOGIES HOLDINGS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →